Compare Inovio Pharmaceuticals Inc (INO) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Las Vegas Sands Corp. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Las Vegas Sands Corp. trades at $36.2 (market cap $23.38B). The key difference: Las Vegas Sands Corp. is far larger — about 208.4× Inovio Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Las Vegas Sands Corp. for 72 Days on average.
| INO | LVS | |
|---|---|---|
Market Cap | $112.19M | $23.38B |
Volume | 3,201,278 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $69.49 |
52-Week Low | $0.66 | $35.81 |
Typical Hold Time | 43 Days | 72 Days |
Enterprise Value | $83.51M | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
LVS trades at $36.17, up 1.01% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 12.59% net margin and 134.29% ROE, supported by $13.02B in 2025 revenue. Analysts are bullish with a $59.78 consensus target, but the stock faces headwinds from high debt levels and a recent Q2 2026 earnings miss.
The outlook for LVS is mixed; solid fundamentals and analyst support suggest upside, but technical weakness and leverage risks warrant caution. Investment opportunity lies in valuation discount versus peers, while risks include debt servicing and Macao regulatory exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
